These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1101901)

  • 21. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.
    Gibson TP; Matusik J; Matusik E; Nelson HA; Wilkinson J; Briggs WA
    Clin Pharmacol Ther; 1975 Apr; 17(4):395-9. PubMed ID: 1122681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid.
    Peretti E; Karlaganis G; Lauterburg BH
    J Pharmacol Exp Ther; 1987 Nov; 243(2):686-9. PubMed ID: 3681700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levels of acetyl hydrazines and rate of acetylation of isoniazid in adult tuberculosis patients.
    Bhalerao EB; Bhide SV
    Indian J Physiol Pharmacol; 1985; 29(2):83-8. PubMed ID: 4093196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoniazid acetylation metabolic ratio during maturation in children.
    Pariente-Khayat A; Rey E; Gendrel D; Vauzelle-Kervroëdan F; Crémier O; d'Athis P; Badoual J; Olive G; Pons G
    Clin Pharmacol Ther; 1997 Oct; 62(4):377-83. PubMed ID: 9357388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies of serial plasma Isoniazid concentrations with different doses of a slow-release preparation of Isoniazid.
    Sarma GR; Kailasam S; Mitchison DA; Nair NG; Radhakrishna S; Tripathy SP
    Tubercle; 1975 Dec; 56(4):314-23. PubMed ID: 779186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
    Horai Y; Ishizaki T; Sasaki T; Koya G; Matsuyama K; Iguchi S
    Br J Clin Pharmacol; 1982 Mar; 13(3):361-74. PubMed ID: 7059436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population screening for isoniazid acetylator phenotype.
    Seifart HI; Parkin DP; Botha FJ; Donald PR; Van Der Walt BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(2):127-34. PubMed ID: 11499851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Enzymatic induction during isoniazid therapy (author's transl)].
    Micheletti C; Percheron F; Foglietti MJ
    Pathol Biol (Paris); 1979 Oct; 27(8):479-82. PubMed ID: 392418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Genetic polymorphism of isoniazid acetylation in Chilean patients with tuberculosis].
    Ligueros M; Cruz Coke R; Neira S; Saavedra H; Kramer V; Prieto JC; Gelman M; Saavedra A; Nuñez A; Pescio S
    Rev Med Chil; 1989 Dec; 117(12):1339-43. PubMed ID: 2519370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Testing for heterogeneity in genetic polymorphism of N-acetylation using isoniazid by metameters--probit, logit, and arcsine transformation].
    Kohno H; Mori M; Katayama T
    Kekkaku; 1993 Aug; 68(8):511-6. PubMed ID: 8377325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfadimidine and isoniazid loading in man and laboratory rats. Pharmacokinetic and pharmacogenetic results on drug acetylation.
    Dubbels R; Kattner E; Sell-Maurer D; Schloot W
    Arzneimittelforschung; 1980; 30(9):1574-9. PubMed ID: 7193028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetylation phenotype in rheumatoid arthritis.
    Oka M; Seppälä O
    Scand J Rheumatol; 1978; 7(1):29-30. PubMed ID: 675172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
    Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of various isoniazid slow releasing matrix preparations for intermittent chemotherapy of tuberculosis.
    Hodgkin MM; Eidus L; Hershfield ES
    Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):349-65. PubMed ID: 461989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical pharmacology of isoniazid (a review of the literature)].
    Ivleva AIa
    Probl Tuberk; 1979 Jan; (1):18-26. PubMed ID: 368763
    [No Abstract]   [Full Text] [Related]  

  • 37. [The pharmacokinetics of isoniazid in children (author's transl)].
    Advenier C; Saint-Aubin A; Scheinmann P; Paupe J
    Rev Fr Mal Respir; 1981; 9(5):365-74. PubMed ID: 7323401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Simultaneous study of the induction effect of rifampicin and the phenotype for acetylation of isoniazid in 21 patients with tuberculosis undergoing a combination treatment].
    Chailleux E; Ordronneau J; Le Normand Y; Kergueris MF; Larousse C
    Rev Fr Mal Respir; 1980; 8(3):219-24. PubMed ID: 7187065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for isoniazid (NIH)-induced liver dysfunction.
    Dickinson DS; Bailey WC; Hirschowitz BI; Soong SJ; Eidus L; Hodgkin MM
    J Clin Gastroenterol; 1981 Sep; 3(3):271-9. PubMed ID: 7288121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of isoniazid half-life from salivary samples.
    Suryawati S; Santoso B
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):18-22. PubMed ID: 3957485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.